Fennec Pharmaceuticals Inc
FENC8.750USD
-0.170-1.91%
Close 07/17, 16:00（ET）Quotes delayed by 15 min
241.45MMarket Cap
LossP/E TTM
More Details of Fennec Pharmaceuticals Inc Company
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
Ticker SymbolFENC
Company nameFennec Pharmaceuticals Inc
IPO dateJun 05, 2001
Founded at2011
CEOMr. Jeffrey S. (Jeff) Hackman
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 05
AddressPO Box 13628
CityRESEARCH TRIANGLE PARK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27709
Phone19196364530
Websitehttps://fennecpharma.com/
Ticker SymbolFENC
IPO dateJun 05, 2001
Founded at2011
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
213.82K
--
Mr. Jeffrey S. (Jeff) Hackman
Mr. Jeffrey S. (Jeff) Hackman
Chief Executive Officer, Director
Chief Executive Officer, Director
15.00K
--
Dr. Pierre Sargis Sayad, Ph.D.
Dr. Pierre Sargis Sayad, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Marco Maria Brughera
Dr. Marco Maria Brughera
Independent Director
Independent Director
--
--
Dr. Jodi A. Cook
Dr. Jodi A. Cook
Independent Director
Independent Director
--
--
Mr. Robert C. Andrade
Mr. Robert C. Andrade
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris A. Rallis
Mr. Chris A. Rallis
Independent Director
Independent Director
--
--
Mr. Rostislav C. (Rosty) Raykov
Mr. Rostislav C. (Rosty) Raykov
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
213.82K
--
Mr. Jeffrey S. (Jeff) Hackman
Mr. Jeffrey S. (Jeff) Hackman
Chief Executive Officer, Director
Chief Executive Officer, Director
15.00K
--
Dr. Pierre Sargis Sayad, Ph.D.
Dr. Pierre Sargis Sayad, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Marco Maria Brughera
Dr. Marco Maria Brughera
Independent Director
Independent Director
--
--
Dr. Jodi A. Cook
Dr. Jodi A. Cook
Independent Director
Independent Director
--
--
Mr. Robert C. Andrade
Mr. Robert C. Andrade
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
8.75M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 21
Updated: Wed, May 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Southpoint Capital Advisors LP
14.76%
ESSETIFIN S.p.A.
14.46%
Sonic GP LLC
8.72%
Solas Capital Management, LLC
8.15%
Rosalind Advisors, Inc.
6.46%
Other
47.46%
Shareholders
Shareholders
Proportion
Southpoint Capital Advisors LP
14.76%
ESSETIFIN S.p.A.
14.46%
Sonic GP LLC
8.72%
Solas Capital Management, LLC
8.15%
Rosalind Advisors, Inc.
6.46%
Other
47.46%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.60%
Corporation
14.46%
Investment Advisor/Hedge Fund
9.60%
Investment Advisor
6.44%
Individual Investor
1.93%
Private Equity
0.96%
Research Firm
0.73%
Pension Fund
0.12%
Bank and Trust
0.11%
Other
26.05%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
154
20.43M
73.99%
-2.39M
2025Q1
168
20.37M
74.06%
-2.08M
2024Q4
167
20.62M
74.91%
-1.43M
2024Q3
164
19.62M
71.63%
-1.98M
2024Q2
158
19.15M
70.00%
-1.44M
2024Q1
141
18.58M
68.58%
-2.09M
2023Q4
134
19.76M
74.92%
-109.52K
2023Q3
133
18.84M
71.34%
-1.09M
2023Q2
134
18.61M
70.46%
-33.59K
2023Q1
140
17.58M
66.55%
-2.50M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Southpoint Capital Advisors LP
4.08M
14.76%
--
--
Apr 07, 2025
ESSETIFIN S.p.A.
3.99M
14.46%
--
--
Apr 07, 2025
Sonic GP LLC
2.41M
8.72%
--
--
Apr 07, 2025
Solas Capital Management, LLC
2.25M
8.15%
--
--
Apr 07, 2025
Rosalind Advisors, Inc.
1.78M
6.46%
+522.97K
+41.51%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.14M
4.13%
+22.63K
+2.02%
Mar 31, 2025
The Vanguard Group, Inc.
964.62K
3.49%
-5.13K
-0.53%
Mar 31, 2025
Harbert Fund Advisors, Inc
466.87K
1.69%
--
--
Mar 31, 2025
State Street Global Advisors (US)
338.13K
1.22%
-1.58K
-0.47%
Mar 31, 2025
Geode Capital Management, L.L.C.
311.33K
1.13%
+8.24K
+2.72%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares Micro-Cap ETF
0.04%
Franklin US Small Cap Multifactor Index ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.04%
Franklin US Small Cap Multifactor Index ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
